Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells

Cytotherapy

Volumn 15, Issue 5, 2013, Pages 620-626

  Lamers, Cor H J ^a   Van Elzakker, Pascal ^a   Van Steenbergen, Sabine C L ^a   Luider, Barbara A ^a   Groot, Corrien ^a   Van Krimpen, Brigitte A ^a   Vulto, Arnold ^a   Sleijfer, Stefan ^a   Debets, Reno ^a   Gratama, Jan Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

anti CD3 mAb; chimeric antigen receptor; clinical trial; human T lymphocytes; RetroNectin; retroviral vectors; stability

Indexed keywords

CARBONATE DEHYDRATASE; CD3 ANTIBODY; FIBRONECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; OKT 3; RETROVIRUS VECTOR;

ADOPTIVE TRANSFER; ARTICLE; CELL COUNT; CELL ENGINEERING; CELL EXPANSION; CELL THERAPY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; EX VIVO GENE TRANSFER; FLOW CYTOMETRY; GENETIC ENGINEERING; GIBBON LEUKEMIA VIRUS; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ADULT; ANTIGENS, CD27; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL ENGINEERING; CELL LINE; CELL- AND TISSUE-BASED THERAPY; FIBRONECTINS; HUMANS; KIDNEY NEOPLASMS; MALE; MUROMONAB-CD3; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84875725221     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2012.12.006     Document Type: Article

References (21)

1. T.S. Park, S.A. Rosenberg, and R.A. Morgan Treating cancer with genetically engineered T cells Trends Biotechnol 29 2011 550 557
2. P.F. Robbins, R.A. Morgan, S.A. Feldman, J.C. Yang, R.M. Sherry, and M.E. Dudley Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 29 2011 917 924
3. M. Kalos, B.L. Levine, D.L. Porter, S. Katz, S.A. Grupp, and A. Bagg T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73
4. C. June, S.A. Rosenberg, M. Sadelain, and J.S. Weber T-cell therapy at the threshold Nat Biotechnol 30 2012 611 614
5. D.E. Gilham, R. Debets, M. Pule, R.E. Hawkins, and H. Abken CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe Trends Mol Med 18 2012 377 384
6. C.H. Lamers, R.A. Willemsen, B.A. Luider, R. Debets, and R.L. Bolhuis Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer Cancer Gene Ther 9 2002 613 623
7. C.H. Lamers, R.A. Willemsen, P. van Elzakker, B.A. van Krimpen, J.W. Gratama, and R. Debets Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer Cancer Gene Ther 13 2006 503 509
8. C. Lamers, P. van Elzakker, S. Langeveld, S. Sleijfer, and J. Gratama Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene Cytotherapy 8 2006 542 553
9. C.H. Lamers, S. Sleijfer, A.G. Vulto, W.H. Kruit, M. Kliffen, and R. Debets Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J Clin Oncol 24 2006 e20 e22
10. E. Oosterwijk, D.J. Ruiter, P.J. Hoedemaeker, E.K. Pauwels, U. Jonas, and J. Zwartendijk Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney Int J Cancer 38 1986 489 494
11. Lamers CHJ, Sleijfer S, Steenbergen van SCL, Elzakker van P, Krimpen van BA, Groot C, et al. Treatment of metastatic Renal Cell Carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. In press.
12. C.H. Lamers, P. van Elzakker, B.A. Luider, S.C. van Steenbergen, S. Sleijfer, and R. Debets Retroviral vectors for clinical immunogene therapy are stable for up to 9 years Cancer Gene Ther 15 2008 268 274
13. A.C. Webster, T. Pankhurst, F. Rinaldi, J.R. Chapman, and J.C. Craig Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data Transplantation 81 2006 953 965
14. C.H. Lamers, R.J. van de Griend, E. Braakman, C.P. Ronteltap, J. Benard, and G. Stoter Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy Int J Cancer 51 1992 973 979
15. H. Uemura, E. Okajima, F.M.J. Debruyne, and E. Oosterwijk Internal image antiidiotype antibodies related to renal-cell carcinoma-associated antigen G250 Int J Cancer 56 1994 609 614
16. F. Herbst, C.R. Ball, O. Zavidij, S. Fessler, M. Schmidt, and H. Veelken 10-year stability of clinical-grade serum-free gamma-retroviral vector-containing medium Gene Ther 18 2011 210 212
17. C. Baleriola, H. Johal, B. Jacka, S. Chaverot, S. Bowden, and S. Lacey Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at -20 degrees C and -70 degrees C J Clin Microbiol 49 2011 3163 3167
18. J. Chen, L. Reeves, and K. Cornetta Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors Hum Gene Ther 12 2001 61 70
19. C.H. Lamers, R.A. Willemsen, P.M. van Elzakker, J.W. Gratama, and R. Debets Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors J Immunother 32 2009 272 279
20. Y.J. Kwon, G. Hung, W.F. Anderson, C.A. Peng, and H. Yu Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis J Virol 77 2003 5712 5720
21. M.T. Mazur, R.S. Seipert, D. Mahon, Q. Zhou, and T. Liu A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry AAPS J 14 2012 530 541